1-4 of 4
Andre T. Brunetto
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase I, Dose-Escalation Study of the Multitargeted Receptor Tyrosine Kinase Inhibitor, Golvatinib, in Patients with Advanced Solid Tumors

Free
L. Rhoda Molife, Emma Jane Dean, Montserrat Blanco-Codesido, Matthew G. Krebs, Andre T. Brunetto, Alastair Peter Greystoke, Gennaro Daniele, Lucy Lee, Galina Kuznetsov, Khin Than Myint, Karen Wood, Begoña de las Heras, Malcolm Richard Ranson
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (24): 6284–6294.
https://doi.org/10.1158/1078-0432.CCR-14-0409
Published: 14 December 2014
View articletitled, A Phase I, Dose-Escalation Study of the Multitargeted Receptor Tyrosine Kinase Inhibitor, Golvatinib, in Patients with Advanced Solid Tumors
Open the PDF for A Phase I, Dose-Escalation Study of the Multitargeted Receptor Tyrosine Kinase Inhibitor, Golvatinib, in Patients with Advanced Solid Tumors in another window
Journal Articles

Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study

Free
Victor Moreno García, David Olmos, Carlos Gomez-Roca, Philippe A. Cassier, Rafael Morales-Barrera, Gianluca Del Conte, Elisa Gallerani, Andre T. Brunetto, Patrick Schöffski, Silvia Marsoni, Jan H.M. Schellens, Nicolas Penel, Emile Voest, Jeffrey Evans, Ruth Plummer, Richard H. Wilson, Jean Charles Soria, Josep Tabernero, Jaap Verweij, Stan B. Kaye
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (22): 5663–5671.
https://doi.org/10.1158/1078-0432.CCR-14-0719
Published: 13 November 2014
View articletitled, Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study
Open the PDF for Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study in another window
Includes: Supplementary data
Journal Articles

First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors

Free
André T. Brunetto, Joo Ern Ang, Rohit Lal, David Olmos, L. Rhoda Molife, Rebecca Kristeleit, Ann Parker, Isabel Casamayor, Muyibat Olaleye, Anna Mais, Bernhard Hauns, Vera Strobel, Bernd Hentsch, Johann S. de Bono
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (19): 5494–5504.
https://doi.org/10.1158/1078-0432.CCR-13-0735
Published: 01 October 2013
View articletitled, First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors
Open the PDF for First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies

Free
David Olmos, Douglas Barker, Rohini Sharma, Andre T. Brunetto, Timothy A. Yap, Anne B. Taegtmeyer, Jorge Barriuso, Hanine Medani, Yan Y. Degenhardt, Alicia J. Allred, Deborah A. Smith, Sharon C. Murray, Thomas A. Lampkin, Mohammed M. Dar, Richard Wilson, Johann S. de Bono, Sarah P. Blagden
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (10): 3420–3430.
https://doi.org/10.1158/1078-0432.CCR-10-2946
Published: 15 May 2011
View articletitled, Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies
Open the PDF for Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies in another window
Includes: Supplementary data